JP2021511035A5 - - Google Patents

Info

Publication number
JP2021511035A5
JP2021511035A5 JP2020539080A JP2020539080A JP2021511035A5 JP 2021511035 A5 JP2021511035 A5 JP 2021511035A5 JP 2020539080 A JP2020539080 A JP 2020539080A JP 2020539080 A JP2020539080 A JP 2020539080A JP 2021511035 A5 JP2021511035 A5 JP 2021511035A5
Authority
JP
Japan
Prior art keywords
sequence
itr
upstream
downstream
noi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020539080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511035A (ja
JP7504458B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014211 external-priority patent/WO2019143950A2/en
Publication of JP2021511035A publication Critical patent/JP2021511035A/ja
Publication of JP2021511035A5 publication Critical patent/JP2021511035A5/ja
Application granted granted Critical
Publication of JP7504458B2 publication Critical patent/JP7504458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020539080A 2018-01-19 2019-01-18 Ａａｖ形質導入と関連付けられる自然免疫応答の阻害のための方法および組成物 Active JP7504458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862619468P 2018-01-19 2018-01-19
US62/619,468 2018-01-19
PCT/US2019/014211 WO2019143950A2 (en) 2018-01-19 2019-01-18 Methods and compositions for inhibition of innate immune response associated with aav transduction

Publications (3)

Publication Number Publication Date
JP2021511035A JP2021511035A (ja) 2021-05-06
JP2021511035A5 true JP2021511035A5 (enExample) 2022-02-24
JP7504458B2 JP7504458B2 (ja) 2024-06-24

Family

ID=67301987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020539080A Active JP7504458B2 (ja) 2018-01-19 2019-01-18 Ａａｖ形質導入と関連付けられる自然免疫応答の阻害のための方法および組成物

Country Status (7)

Country Link
US (1) US20200340013A1 (enExample)
EP (1) EP3740572A4 (enExample)
JP (1) JP7504458B2 (enExample)
CN (1) CN111918966B (enExample)
AU (1) AU2019210190B2 (enExample)
CA (1) CA3088538A1 (enExample)
WO (1) WO2019143950A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110904PA (en) 2019-04-12 2021-10-28 Ultragenyx Pharmaceutical Inc Engineered producer cell lines and methods of making and using the same
ES2827599B2 (es) * 2019-11-21 2022-05-05 Fundacion Para La Investigacion Biomedica Del Hospital Univ Nino Jesus Celulas madre mesenquimales para ser usadas como vehiculos de agentes terapeuticos
EP4077643A4 (en) * 2019-12-17 2024-01-17 Nikegen Limited PARVOVIRUS VECTORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2021205250A1 (en) * 2020-01-07 2022-08-18 The University Of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats and methods of their use as promoters
US20250019668A1 (en) * 2021-10-29 2025-01-16 Ultragenyx Pharmaceutical Inc. Engineered cell lines for increased production of recombinant adeno-associated virus (raav)
WO2024123813A1 (en) * 2022-12-05 2024-06-13 The Trustees Of Columbia University In The City Of New York Viral vectors for increasing the specificity of gene expression
CN117701638B (zh) * 2023-12-18 2024-10-18 苏州新芽基因生物技术有限公司 一种抑制残留aav载体质粒和质粒骨架转录活性的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19959045A1 (de) * 1999-12-07 2001-06-28 Deutsches Krebsforsch MCP-1 exprimierende AAV-Expressionsvektoren und deren therapeutische Verwendung
US20110206639A1 (en) * 2004-04-15 2011-08-25 Christie Vermeulen Replication competent viruses capable of silencing virus inhibitory factor expression
US20110070241A1 (en) * 2009-06-30 2011-03-24 Duke University Methods for modulating immune responses to aav gene therapy vectors
CN105229021A (zh) * 2013-03-15 2016-01-06 加利福尼亚大学董事会 在哺乳动物中起抗病毒免疫作用的rna干扰
US11033638B2 (en) * 2015-01-07 2021-06-15 Universität Autonoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes
US20190000943A1 (en) * 2015-08-13 2019-01-03 Aavet Therapeutics, Llc Aav6 vectors for immunotherapy

Similar Documents

Publication Publication Date Title
JP2021511035A5 (enExample)
CN101603042B (zh) 可用于乙型肝炎病毒感染治疗的rna干扰靶点
JP7506670B2 (ja) 脂質ナノ粒子製剤
Wang et al. MiR-125b reduces porcine reproductive and respiratory syndrome virus replication by negatively regulating the NF-κB pathway
Moshiri et al. Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma
CN113286882A (zh) 脂质纳米颗粒制剂
Moore et al. Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors
Mollaie et al. RNAi and miRNA in viral infections and cancers
CN108064292A (zh) RNAi诱导的亨廷顿蛋白基因抑制
JP2017510298A5 (enExample)
WO2011101869A1 (en) Adeno-associated virus 2/8 - micro rna-101 therapy for liver cancer
US20100209491A1 (en) Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv
CN103275971A (zh) 可用于乙型肝炎病毒感染治疗的rna干扰靶点
Sakurai et al. Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a
Peng et al. Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties
JP4545091B2 (ja) Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
Mao et al. Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs
CN109477110B (zh) 抑制mex3b基因的表达的核酸、试剂、及疾病的预防或治疗剂
US8957199B2 (en) Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus
WO2011111072A2 (en) Adeno-associated virus ezh2 shrna (aav ezh2 shrna)therapy for breast cancer
WO2023220719A2 (en) Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting
Wei et al. Inhibition of HBV replication by delivering the dual-gene expression vector pHsa-miR16-siRNA in HepG2. 2.15 cells
JP7441174B2 (ja) Ｂ型肝炎ウイルスの複製阻害組成物
Deng et al. HBx Downregulates miR-422a Expression via Activation of FOXG1/Q1/E1 in HepG2 Cells.
Singh et al. RNA INTERFERENCE TECHNOLOGY: IMPLICATIONS AND APPLICATIONS.